Sara Cetin Sanlialp*
Department of Cardiology, Servergazi State Hospital, Denizli, Turkey
*Corresponding Author: Sara Cetin Sanlialp, Department of Cardiology, Servergazi State Hospital, Denizli, Turkey.
Received: December 23, 2019; Published: January 10, 2020
In 2019, new guidelines on arrhythmia, coronary syndrome, diabetes mellitus, hyperlipidemia and pulmonary embolism were published. Innovations and changes in these areas will already affect the practice of cardiologists in 2020. In this article we aimed to focus on these changes and innovations with main lines in diabetes mellitus and hiperlipidemia.
While the miracle drug of diabetes mellitus was the first drug of choice for metformin years, it was emphasized that the use of SGLT-2 inhibitors and GLP1-RAs agents should be the first choice because it reduces adverse cardiovascular events. It has not been recommended for the first time to measure carotid intima-media thickness, which we have been using for years to estimate cardiovascular risk. Microalbuminuria, a cardiovascular risk marker and renal dysfunction marker, has been recommended to be routinely evaluated in diabetic patients. Reducing HbA1c to less than 7% to prevent microvascular complicationsand this target value should be individualized. It has been proposed to focus on the more flexible HbA1c target in the elderly and the lower HbA1c targets in the young. It was stated that SGTL2 inhibitors should be the first choice drugs in patients with heart failure because they reduce the risk of heart failure and reduce hospitalization in patients with heart failure. however, saxagliptin, a DPP4 inhibitor, has not been recommended for use in patients with heart failure. Since atrial fibrillation is common in diabetic patients, screening of diabetic patients over 65 years of age for atrial fibrillation has been recommended. Mediterranean diet and exercise were recommended in diabetic patients, and the discontinuation of micronutrient use frequently consumed by diabetic patients was emphasized.
Citation: Sara Cetin Sanlialp. “Will the Innovations in Diabetes and Dyslipidemia Affect Our Practice in 2020?". Acta Scientific Nutritional Health 4.2 (2020): 80-81.
Copyright: © 2020 Sara Cetin Sanlialp. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.